Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Aktionärsstruktur

Inhaber in %
Freefloat 94.93
Government Pension Fund - Global (The) 2.32
Vanguard Total International Stock Index Fund 1.26
Vanguard Health Care Fund 1.25
American Funds EuroPacific Growth Fund 0.88
Goldman Sachs GQG Partners International Opportunities Fund 0.78

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2018 2019 2020 2021 2022
Personal am Ende des Jahres 64'400 70'600 76'100 83'100 83'500
Umsatz pro Mitarbeiter in Mio. EUR 0.26 0.27 0.28 0.33 0.43

Bilanz (in Mio. EUR) - Aktiva

2018 2019 2020 2021 2022
Summe Umlaufvermögen 12'184 11'748 14'298 19'376 18'782
Summe Anlagevermögen 24'797 23'668 26'337 51'718 55'091
Summe Aktiva 47'622 46'331 48'816 77'790 80'209

Bilanz (in Mio. EUR) - Passiva

2018 2019 2020 2021 2022
Gesamtverschuldung/ -verbindlichkeiten 15'007 13'759 14'909 22'726 24'301
Summe Fremdkapital 36'595 35'313 37'376 48'784 49'401
Summe Eigenkapital 11'027 11'018 11'440 29'006 30'807
Summe Passiva 47'622 46'331 48'816 77'790 80'209

Adresse

Cambridge Biomedical Campus, CB2 0AA Cambridge
Telefon +44 (20) 3749-5000
URL http://www.astrazeneca.com

Management

Adrian Charles Noel Kemp
Secretary
Ahmed M. Hamdy
Member
Alberto Hegewisch
Chief Medical Officer
Andreas Rummelt
Non-Executive Director
Aradhana Sarin
Chief Financial Officer & Executive Director
Cindy L. Hoots
Chief Digital & Information Officer
David Fredrickson
Executive Vice President-Oncology Business Unit
Deborah DiSanzo
Independent Non-Executive Director
Diana Layfield
Non-Executive Director
Euan A. Ashley
Non-Executive Director
Helen MacPhee
Vice President
Iskra Reic
Executive Vice President-Europe & Canada
Jeffrey Pott
CHRO, Chief Compliance Officer & General Counsel
Jonathan Thomas Charles Slade
Group Treasurer
Katarina Ageborg
Chief Compliance Officer & EVP-Sustainability
Kevin G. Lokay
Head-Change Implementation
Marc Pierre Jean Dunoyer
Chief Strategy Officer
Marcus Wallenberg
Independent Non-Executive Director
Margareta Elisabeth Björk
Senior VP & Head-Late-stage Development
Mark White
Global Franchise Head-Fasenra
Menelas NICOLAS Pangalos
EVP-Biopharmaceuticals Research & Development
Michel Demaré
Chairman
Nazneen Rahman
Independent Non-Executive Director
Pam P. Cheng
Executive VP-Operations & Information Technology
Pascal Soriot
Chief Executive Officer & Executive Director
Philip Arthur John Broadley
Senior Independent Non-Executive Director
Regina Fritsche Danielson
SVP, Head-Research & Early Development
Ruud Dobber
Executive VP-Biopharmaceuticals Business
Sarah Miksinski
Senior Director-Global Regulatory Affairs
Sherilyn D. McCoy
Independent Non-Executive Director
Sjoerd Hubben
Vice President-Global Government Affairs & Policy
Susan Mary Galbraith
Executive VP-Oncology Research & Development
Tony Mok
Independent Non-Executive Director
Tyrell J. Rivers
Executive Director-Corporate Development

Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen